This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Freeline Therapeutics Holdings Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Michael Parini

Algemeen directeur

US$2.2m

Totale compensatie

Percentage CEO-salaris	27.4%
Dienstverband CEO	2yrs
Eigendom CEO	1.1%
Management gemiddelde ambtstermijn	1.6yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Michael Parini's beloning veranderd ten opzichte van Freeline Therapeutics Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-US$61m
Dec 31 2022	US$2m	US$591k	-US$89m
Sep 30 2022	n/a	n/a	-US$101m
Jun 30 2022	n/a	n/a	-US$117m
Mar 31 2022	n/a	n/a	-US$132m
Dec 31 2021	US$1m	US$419k	-US$140m

Compensatie versus markt: De totale vergoeding ($USD 2.16M ) Michael } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 486.57K ).

Compensatie versus inkomsten: De vergoeding van Michael is gestegen terwijl het bedrijf verliesgevend is.

CEO

Michael Parini (48 yo)

2yrs

Tenure

US$2,160,000

Compensatie

Mr. Michael J. Parini, JD., serves as Chief Executive Officer & Executive Director at Freeline Therapeutics Limited since August 16, 2021. He had been President and Chief Operating Officer at Freeline Ther...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Parini	CEO & Executive Director	2yrs	US$2.16m	1.1% € 180.7k
Paul Schneider	CFO & Director	1.3yrs	geen gegevens	geen gegevens
Henning Stennicke	Chief Scientific Officer	1.4yrs	geen gegevens	geen gegevens
Nicole Jones	Chief People Officer	1.1yrs	geen gegevens	geen gegevens
James Bircher	Chief Technical Operations Officer	2.1yrs	geen gegevens	geen gegevens
Pamela Foulds	Chief Medical Officer	1.8yrs	geen gegevens	geen gegevens
Naomi Aoki	Senior Vice President of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Amy Spandau	Interim Head of Finance	no data	geen gegevens	geen gegevens

1.6yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 78F0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Parini	CEO & Executive Director	2yrs	US$2.16m	1.1% € 180.7k
Paul Schneider	CFO & Director	less than a year	geen gegevens	geen gegevens
Julia Gregory	Independent Non-Executive Director	3.8yrs	US$172.00k	geen gegevens
Colin Love	Independent Non Executive Director	2.4yrs	US$93.00k	geen gegevens
Christopher Hollowood	Independent Chairman	7.7yrs	US$93.00k	geen gegevens
Jeffrey Chodakewitz	Independent Non-Executive Director	4yrs	US$166.00k	geen gegevens
Martin Andrews	Independent Non-Executive Director	4.8yrs	US$154.00k	geen gegevens

3.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 78F0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

This company listing is no longer active

Freeline Therapeutics Holdings Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2023

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2022

Freeline Therapeutics Holdings plc Appoints Paul Schneider as Chief Financial Officer

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

High number of new directors

Recent updates

Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Freeline Therapeutics Files Form 15

Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index

Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN).

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for for $9.8 million.

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for approximately $140 million.

Freeline Therapeutics Holdings plc Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 Galileo-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Freeline Therapeutics Holdings plc Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-Linked Parkinson's Disease

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2023

Freeline Therapeutics Holdings Regains Compliance with the Nasdaq Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc Receives ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

Freeline Therapeutics Holdings plc Announces the Publication of Preclinical Proof-Of-Concept Data for Its Gene Therapy Candidate for Fabry Disease, FLT190

Freeline Initiates Dosing of Second Cohort in Marvel-1 Trial of Flt190 Gene Therapy Candidate for People with Fabry Disease

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2022

Freeline Therapeutics Holdings plc Appoints Paul Schneider as Chief Financial Officer

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

Freeline Therapeutics Holdings plc Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

Freeline Therapeutics Holdings plc Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial

High number of new directors

Chief Scientific Officer Romuald Corbau has left the company

CEO & Director Theresa Heggie has left the company

Chief Development Officer Jan Thirkettle has left the company

Freeline Doses Second Patient of Phase 1/2 Marvel-1 Clinical Trial for Fabry Disease

Freeline Therapeutics Holdings plc Presents Data Highlighting Platform Technology At the American Society of Gene and Cell Therapy Annual Meeting 2021

CFO & Head of Corporate Development has left the company

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd